Caxton Associates LP Makes New $918,000 Investment in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Caxton Associates LP bought a new stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 16,588 shares of the company's stock, valued at approximately $918,000.

A number of other large investors also recently modified their holdings of the company. Barclays PLC boosted its holdings in shares of Tarsus Pharmaceuticals by 345.9% during the third quarter. Barclays PLC now owns 98,663 shares of the company's stock valued at $3,246,000 after acquiring an additional 76,538 shares during the period. JPMorgan Chase & Co. grew its position in Tarsus Pharmaceuticals by 2,088.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 440,167 shares of the company's stock worth $14,477,000 after acquiring an additional 420,057 shares during the last quarter. Harbor Capital Advisors Inc. increased its position in Tarsus Pharmaceuticals by 22.1% in the fourth quarter. Harbor Capital Advisors Inc. now owns 22,113 shares of the company's stock worth $1,224,000 after purchasing an additional 4,008 shares during the period. Assenagon Asset Management S.A. increased its stake in Tarsus Pharmaceuticals by 0.5% in the fourth quarter. Assenagon Asset Management S.A. now owns 1,146,812 shares of the company's stock valued at $63,499,000 after purchasing an additional 5,565 shares in the last quarter. Finally, R Squared Ltd acquired a new position in shares of Tarsus Pharmaceuticals during the fourth quarter worth about $53,000. 90.01% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

TARS has been the topic of a number of recent analyst reports. Guggenheim lifted their target price on Tarsus Pharmaceuticals from $78.00 to $84.00 and gave the company a "buy" rating in a research report on Friday, May 2nd. Oppenheimer upped their price objective on Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the stock an "outperform" rating in a report on Wednesday, January 22nd. Barclays lowered their target price on shares of Tarsus Pharmaceuticals from $62.00 to $60.00 and set an "overweight" rating for the company in a report on Wednesday, February 26th. The Goldman Sachs Group increased their price target on shares of Tarsus Pharmaceuticals from $46.00 to $51.00 and gave the stock a "neutral" rating in a research report on Monday, May 5th. Finally, Jefferies Financial Group boosted their price target on shares of Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the stock a "buy" rating in a research report on Thursday, March 6th. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, Tarsus Pharmaceuticals presently has an average rating of "Buy" and a consensus price target of $66.33.

Tarsus Pharmaceuticals Trading Down 4.8 %

NASDAQ:TARS traded down $2.27 on Friday, hitting $44.87. 529,648 shares of the stock were exchanged, compared to its average volume of 689,849. The stock has a fifty day moving average of $48.26 and a 200-day moving average of $49.07. The company has a current ratio of 5.42, a quick ratio of 5.38 and a debt-to-equity ratio of 0.30. Tarsus Pharmaceuticals, Inc. has a fifty-two week low of $20.08 and a fifty-two week high of $57.28. The stock has a market cap of $1.89 billion, a PE ratio of -11.78 and a beta of 0.94.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The company reported ($0.64) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.69) by $0.05. The firm had revenue of $78.34 million for the quarter, compared to analysts' expectations of $72.50 million. Tarsus Pharmaceuticals had a negative return on equity of 55.86% and a negative net margin of 103.64%. As a group, equities analysts expect that Tarsus Pharmaceuticals, Inc. will post -3.17 earnings per share for the current fiscal year.

Insider Transactions at Tarsus Pharmaceuticals

In other news, CEO Bobak R. Azamian sold 8,534 shares of the firm's stock in a transaction dated Thursday, March 20th. The shares were sold at an average price of $50.11, for a total transaction of $427,638.74. Following the completion of the transaction, the chief executive officer now directly owns 53,635 shares of the company's stock, valued at approximately $2,687,649.85. This trade represents a 13.73 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Dianne C. Whitfield sold 2,137 shares of Tarsus Pharmaceuticals stock in a transaction on Thursday, March 20th. The shares were sold at an average price of $50.11, for a total value of $107,085.07. Following the completion of the transaction, the insider now owns 46,355 shares of the company's stock, valued at approximately $2,322,849.05. The trade was a 4.41 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 32,542 shares of company stock valued at $1,581,173 in the last three months. 8.25% of the stock is currently owned by corporate insiders.

Tarsus Pharmaceuticals Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.